Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Microarrays Changes Name to Decision Biomarkers

NEW YORK, Aug. 15 (GenomeWeb News) - Clinical Microarrays has changed its name to Decision Biomarkers, the company said today.


The company also said it has relocated to Waltham, Mass., from Natick, Mass.


According to Decision Biomarkers President and CEO Roger Dowd, the name change is a result of the company's efforts to "better communicate the scope and value of what [it] is preparing to deliver to the market."


The company is currently preparing to commercialize a fully-automated, multiplexed immunoassay system for quantitating protein biomarkers.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.